Introduction
Multiple myeloma (MM) is a malignancy of plasma cells that responds to a limited set of treatment options and is an often incurable disease with a short survival time, especially in older adults. 1 During the past decade, new MM drugs have been developed and clinical trials with new therapies are ongoing. [2] [3] [4] These new agents and their combinations with chemotherapies have resulted in highly effective regimens, with increased response rates in both the frontline setting for patients not eligible for high-dose therapy/stem cell transplantation and for patients whose disease has relapsed or become resistant to conventional therapy. 5, 6 However, some of these new agents exhibit significant toxicity and eventually patients develop resistance to these drugs. 7, 8 Therefore, there is the need to add more targeted approaches for treatment in order to improve the anti-myeloma efficacy and enhance the safety and tolerability of these regimens.
IL-6 and the downstream activation of JAK-dependent and JAK-independent signaling pathways have a critical role in the pathophysiology of MM by acting as a potent proliferation, survival and drug resistance determinant for myeloma cells. 9, 10 Among the major signaling pathways downstream of IL-6 are the JAK/STAT3 and Ras/MAPK proteins, which are implicated in survival and proliferation of myeloma cells, respectively. 11, 12 Thus, a small-molecule inhibitor of JAK and downstream signaling could provide clinical benefits in MM. There is no JAK targeted therapy currently available for patients with MM. Compounds including curcumin, atiprimod, the tyrosine kinase inhibitor AG490 and the pan-JAK inhibitors pyridone 6, and INCB20 lead to inhibition of IL-6-induced MM cell survival associated with inhibition of STAT3 activity. 11, [13] [14] [15] [16] [17] However, none of these agents is currently approved for treatment of MM.
AZD1480 is a potent, adenosine triphosphate competitive, small-molecule inhibitor of JAK2 kinase, 18 which is in early phase clinical trials for treatment of myelofibrosis. In this study, we investigated the effect of AZD1480 on IL-6/JAK2 downstream effectors and its biological consequences on human myeloma-derived cell lines. These model cell lines (U266 and Kms.11) express constitutively activated STAT3 and are IL-6 growth stimulated. Kms.11 cells overexpress FGFR3, which is frequently translocated in MM patients. We show that AZD1480 is a potent JAK2 inhibitor that can suppress growth, survival, as well as FGFR3 and STAT3 signaling, and downstream targets including Cyclin D2 in human MM cells.
Materials and methods

Drugs and cytokines
AZD1480 was provided by AstraZeneca (Waltham, MA, USA). For in vitro experiments, AZD1480 was dissolved in 100% dimethyl sulphoxide (DMSO) to prepare a 10 mM stock and stored at À20 1C. For in vivo experiments, AZD1480 was formulated daily in purified, sterile water supplemented with 0.5% Hypromellose and 0.1% Tween 80. Doxorubicin was provided by Sigma (St Louis, MO, USA) and melphalan was obtained from a pharmacy; both drugs were dissolved in RPMI-1640 medium to prepare millimolar range stocks and stored at 4 or À20 1C, respectively. IL-6 (R&D Systems, Minneapolis, MN, USA) was reconstituted in sterile 1 Â phosphate-buffered saline containing 0.1% bovine serum albumin to prepare a 10 mg/ml stock and stored at À20 1C. NF449 and JAK2 inhibitor IV were purchased from Calbiochem (San Diego, CA, USA); NF007 and FGFR inhibitor were purchased from Tocris Bioscience (Ellisville, MO, USA).
Cell lines and cell culture conditions
Human myeloma U266, RPMI 8226, MM1.S, IM-9 and NCI-H929 cell lines, as well as bone marrow (BM) stromal cells (HS-5), were obtained from the American Type Culture Collection (Manassas, VA, USA). The OPM-2 cells were purchased from the European Collection of Cell Culture. The Kms.11 and Kms.18 cells were a gift from Dr PL Bergsagel. Cells were maintained in RPMI-1640 medium containing 10% fetal bovine serum and 50 U/ml penicillin and streptomycin at 37 1C in an atmosphere of 5% CO 2 and passaged twice a week.
Isolation of CD138
þ cells from primary peripheral blood (PB) mononuclear cells and BM mononuclear cells BM aspirates were collected from four patients with MM and PB samples were collected from five healthy donors. BM mononuclear cells and PB mononuclear cells were isolated with Ficoll-Hypaque sedimentation (Sigma-Aldrich, St Louis, MO, USA) and enriched for CD138-positive cells by immunomagnetic nanoparticles positive selection method using the EasySep kit (StemCell Technologies, Vancouver, BC, Canada). The yield of MM cells was high (495%). Viability of the MM-cell enriched fractions was 99%. All donors and patients had given informed consent for sample acquisition as a part of a protocol approved by the local Institutional Review Board.
Cocultures with BM stromal cells
BM stromal layers were established by plating HS-5 cells at a density of 250 000 cells per well in 12-well plates for 24 h. For experiments to calculate the percentage of tumor cell death, Kms.11 cells were first labeled with 5 mM CellTrace carboxyfluorescein diacetate, succinimidyl ester (CFSE) (Molecular Probes, Eugene, OR, USA), resuspended in serum-free medium and then applied to the wells containing the HS-5 stromal cells layer at a concentration of 250 000 cells per ml. After 24 h of coculture, AZD1480 was added to the coculture media. Following incubation for 48 h with AZD1480, Kms.11 cells were separated from the stromal layer by carefully pipetting twice with ice-cold phosphate-buffered saline. Tumor cells were stained with 4',6-diamidino-2-phenylindole (DAPI) and analyzed using a flow cytometer with excitation and emission wavelengths appropriate for fluorescein and DAPI. The percent cell death was calculated on the basis of all the DAPI-positive cells after gating on CFSE-positive Kms.11 cells.
Analysis of primary cells by Digital Imaging Microscopy System (DIMSCAN)
Primary cells were cultured at a density of 25 000 cells per well in 96-well plates with RPMI-1640 medium containing 10% fetal bovine serum and 50 U/ml penicillin and streptomycin, and treated with different doses of AZD1480 up to 48 h. To determine the cytotoxicity of AZD1480, cells were assessed by the fluorescence-based DIMSCAN, which uses digital imaging microscopy to quantify viable cells that selectively accumulate fluorescein diacetate.
Cell viability assays
Cells were seeded in 96-well plates at a density of 10 000 cells per well. After 24, 48 or 72 h, cell viability was determined by assaying with MTS ((3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium), inner salt) assay (Promega, Madison, WI, USA). The MTS assay was performed according to the instructions from the supplier. Absorbance was measured at 490 nm with a Chameleon plate reader (Bioscan, Washington, DC, USA).
Apoptosis assay by flow cytometry
Untreated and drug-treated cells were stained with Annexin V and Propidium Iodide using Annexin V-FITC apoptosis detection Kit I (BD Biosciences Pharmingen, San Diego, CA, USA). The percentage of apoptotic and nonviable cells was determined by flow cytometry. At least 50 000 cells were collected with a CyAn ADP Violet (Dako, Carpinteria, CA, USA) cytometer and calculated using the Summit software (Dako). Percent apoptosis was calculated on the basis of all the Annexin V-positive plus the Annexin V/propidium iodide-positive cells. The percent loss of cell viability was calculated considering all the Annexin V-positive plus the propidium iodide-positive and the Annexin V/propidium iodide-positive cells.
Western blot analysis
Cells were washed with ice-cold phosphate-buffered saline containing 0.1 mM sodium orthovanadate, and total proteins were isolated using RIPA lysis buffer, which included protease inhibitors (leupeptin, antipain and aprotinin), 0.5 mM PMSF and 0.2 mM sodium orthovanadate. Protein amounts were quantified using the Bio-Rad protein assay (Bio-Rad Laboratories, Hercules, CA, USA). Equal amounts of proteins were loaded onto a SDS polyacrylamide gel electrophoresis gel, transferred onto nitrocellulose membrane, and probed with the indicated antibody: rabbit polyclonal anti-phospho-JAK2 (Chemicon International, Temecula, CA, USA); rabbit polyclonal anti-STAT3, anti-phospho-STAT3 (Tyr705), anti-phospho-STAT3 (Ser727), anti-p44/42 MAPK and anti-phospho-p44/42 MAPK (Cell Signaling Technology, Danvers, MA, USA); mouse monoclonal anti-c-Myc, rabbit polyclonal anti-Mcl-1, rabbit polyclonal anti-Cyclin-D2 (Santa Cruz Biotechnology, Santa Cruz, CA, USA); mouse monoclonal Bcl-xL antibody (Calbiochem); and mouse monoclonal b-actin antibody (Sigma-Aldrich). Membranes were then washed, reprobed with appropriate horseradish peroxidase-conjugated secondary antibodies (Amersham Biosciences, Buckinghamshire, UK), and developed with SuperSignal chemiluminescent substrate (Pierce Biotechnology, Rockford, IL, USA).
Protein immunoprecipitation
Cell lysates (250 mg protein) were incubated with JAK1, JAK2 antibodies (Cell Signaling Technology) or FGFR3 antibody (Novus Biologicals, Littleton, CO, USA) overnight at 4 1C. To this mixture, washed protein A beads were added and incubated for 1 h at 4 1C. Next, the immunoprecipitates were washed five times with the lysis buffer and proteins were eluted with the SDS sample buffer, loaded on 12% SDS polyacrylamide gel electrophoresis gels and analyzed by western blotting analysis using phospho-JAK1, phospho-JAK2 antibodies (Cell Signaling Technology) or phosphoTyr antibody (Millipore, Temecula, CA, USA).
Kinase assay
Cell-free kinase assays were performed as previously described. 19 Briefly, assays were carried out in 50 ml of kinase buffer (60 mM HEPES-NaOH pH, 7. 22 For establishing the stable activated STAT3 (STAT3c)-expressing cells, plasmids pRC/CMV-vector and pRC/CMV-STAT3c-Flag were transected into Kms.11 cells. At 24 h after transfection, 0.5 mg/ml G418 (Invitrogen, Grand Island, NY, USA) was added for selection. Resistant pools of cells were characterized by western blot and maintained in medium containing 0.2 mg/ml G418. Kms.11 cells were also transiently transfected with the pRK7 vectors carrying FLAG-tagged wild-type and Y373C-FGFR3 constructs, which were described previously. 19 The vector containing no insert was pcDNA3.
Animal model studies , mice were divided into one control group and one treated group (10/group), which were dosed orally with the vehicle or AZD1480 (30 mg/kg), respectively. Mice were dosed twice a day for 7 days a week. At the dose of AZD1480 indicated, no lethal toxicity or weight loss (greater than 10% body weight) was observed amongst treated animals. Tumors were measured every 3-4 days with vernier calipers, and tumor volumes were calculated by the following formula: 0.5 Â (larger diameter) Â (smaller diameter). All mice were maintained under specific pathogen-free conditions and were used in compliance with protocols approved by the local Institutional Animal Care and Use Committee.
Statistical analysis and software
The data shown represent mean values of at least three independent experiments and expressed as mean ± s.d. Statistical analysis was performed by the Student's t-test, using the statistical software GraphPad Prism 4 (GraphPad Software, Inc., La Jolla, CA, USA). Statistical significance was set at a level of Po0.05. Four patients were selected based on the criteria that this is a sufficient sample size to rule out lack of drug action if there is consistent drug activity demonstrated in all samples (Po0.02). The Mann-Whitney test was used to calculate the P-value in Figure 1c and Figure 2 . The statistical analysis in Figure 3a was performed with two-way analysis of variance. The statistical significance of the downregulation of Cyclin D2 in Figure 3b was calculated using the integrated density value (IDV) values normalized to those of b-actin, which were determined by the densitometry software AlphaImager. The 50% inhibitory concentration (IC 50 ) values in Table 1 and the combination index values in Table 2 were calculated by the software Compusyn; the descriptions in Table 2 are based on the ranges of combination index refined from those described by Chou. 23 
Results
AZD1480 inhibits proliferation and induces apoptosis of human myeloma cell lines
We investigated the effects of treatment with AZD1480 on a panel of human myeloma cell lines. We first determined the effect of AZD1480 on the proliferation of U266, Kms.11 and 8226 cells ( Figure 1a ). MTS assays showed that AZD1480 markedly inhibits the growth of U266, Kms.11 and 8226 cells in a time-and dose-dependent manner. The data also indicate that AZD1480 is more potent in U266 and Kms.11 cells than in 8226 cells for inhibiting proliferation. IC 50 value for inhibition of proliferation at 48 h is approximately 2 mM for U266 cells and approximately 1 mM for Kms.11 cells; in the same cell lines the IC 50 at 72 h is approximately 1 and 0.5 mM, respectively. In all, 8226 cells require higher concentrations of AZD1480 with an IC 50 at 72 h of approximately 3 mM. The IC 50 values were determined for a wider variety of myeloma cell lines. Table 1 shows that AZD1480 has broad efficacy, which correlates not only with the presence of activated STAT3 but also with the expression of FGFR3. Cells lacking both phospho-STAT3 and FGFR3 are less sensitive than cells possessing activated STAT3 Table 1 .
The apoptotic effect of AZD1480 was determined in the two more sensitive cell lines, U266 and Kms.11 ( Figure 1b) . Exposure to AZD1480 induces apoptosis of both U266 and Figure 1c shows that the viability of human peripheral blood mononuclear cells was not affected at concentrations in the IC 50 range for inducing apoptosis of Kms.11 cells. As IL-6 has a prominent role in MM, 9,10 we evaluated whether AZD1480 suppresses the IL-6-induced proliferation and survival of myeloma cells that have been reported to be growth stimulated by IL-6. 13, 24 The MTS assay ( Figure 2a) showed that 0.5 mM AZD1480 at 48 h completely inhibits IL-6-induced cell proliferation in U266 cells and inhibits approximately 50% of IL-6-induced cell proliferation in Kms.11 cells. U266 and Kms.11 cells treated for 48 h with 2 mM AZD1480 compared with the untreated cells stimulated with IL-6 showed 70 and 50% cell proliferation inhibition, respectively. AZD1480 also inhibits the survival of both cell lines in the presence of IL-6, inducing 50 and 60% apoptosis at 2 mM at 48 h in U266 and Kms.11 cells compared with the untreated controls grown in the presence of IL-6, respectively (Figure 2b) . Therefore, the addition of IL-6, which induced proliferative responses in U266 and Kms.11 cells (20 and 30%, respectively), did not cause a significant shift in IC 50 for U266 cells and did not protect them from AZD1480-mediated inhibition of proliferation and survival. However, Kms.11 cells are less sensitive to AZD1480 in terms of inhibition of proliferation when cultured in the presence of IL-6 but still respond to the drug with IC 50 at 2 mM.
AZD1480 inhibits IL-6-inducible JAK2/STAT3 and MAPK signaling pathways in vitro As JAK family kinases are known to be activated by phosphorylation upon IL-6/gp130 engagement, 25 we examined the effect of AZD1480 on IL-6-dependent JAK2 phosphorylation in myeloma cells pretreated with AZD1480 and then stimulated with IL-6. Figure 3a shows that IL-6-induced phosphorylation of JAK2 was inhibited at 0.25-0.5 mM and virtually abolished at 1 mM in both U266 and Kms.11 cells. The JAK1 phosphorylation was not inhibited at these doses.
It is well established that IL-6 activates distinct downstream signaling pathways: JAK/STAT3 and Ras/MAPK pathways. 12, 26 We therefore investigated whether the blockade of IL-6-inducible activation of JAK2 by AZD1480 would prevent the phosphorylation of STAT3 and MAPK in myeloma cell lines pretreated with AZD1480 and then stimulated with IL-6. Figure 3b shows that the phosphorylation of both STAT3 and ERK1/2 induced by IL-6 in U266 and Kms.11 cells was reduced to basal levels at 0.5-1 mM, and phosphorylation of STAT3 was abolished at 2 mM. We also demonstrated that AZD1480 inhibits constitutive tyrosine phosphorylation of STAT3 but not the serine phosphorylation (data not shown).
To better mimic the in vivo condition, U266 and Kms.11 cells were cultured for 16 h in the presence of IL-6 and then treated with AZD1480. In this setting, we observed a significant decrease of the level of STAT3 and MAPK phosphorylation at 4 h (Figure 3c ) and 24 h post-treatment (data not shown). We also confirmed that 8226 cells lack constitutively activated STAT3, whereas IL-6 stimulated the tyrosine phosphorylation of STAT3 and the activation of MAPK, as previously described.
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AZD1480 suppressed the IL-6-induced phosphorylation of JAK2, STAT3 and MAPK even though phospho-JAK2 levels were downregulated at higher concentrations compared with those required to downregulate phospho-JAK2 levels in U266 and Kms.11 cells (data not shown). Therefore, the inhibition of IL-6-induced growth of myeloma cells by AZD1480 correlates with induction of apoptosis and decreased JAK2, STAT3 and MAPK phosphorylation.
Our observation that the IC 50 for AZD1480, in terms of inhibition of proliferation or survival, was higher than the concentration required to reduce STAT3 activation in myeloma cells may suggest that these cells may not be completely dependent on STAT3 for survival. Figure 3d demonstrates that Kms.11 cells depend on STAT3 for proliferation as downregulation of STAT3 by siRNA results in 50% inhibition of proliferation compared with cells transfected with control siRNA. Downregulation of STAT3 mRNA levels was confirmed by quantitative real-time PCR 72 h post transfection (approximately 70% inhibition compared with control) (data not shown). To determine if STAT3 is involved in the response to AZD1480, we performed experiments in Kms.11 cells transfected with constitutive STAT3c (Figure 3e ). STAT3c rescues Kms.11 cells from AZD1480-mediated loss of viability, consistent with role of STAT3 in the biological effects mediated by AZD1480. Nevertheless, we do not exclude the possibility that other pathways may be involved in the response to AZD1480.
As AZD1480 inhibits proliferation and induces apoptosis associated with inhibition of IL-6-inducible STAT3 phosphorylation, we investigated the effect of AZD1480 on direct or indirect STAT3 targets in MM that have key roles in cell-cycle regulation (Cyclin D2), proliferation (c-Myc) and survival (Mcl-1 and Bcl-xL). 11, 28 We first analyzed the levels of these proteins in U266 and Kms.11 cells cultured for 16 h in the presence of IL-6 and then treated with AZD1480. Figure 4a shows that IL-6 upregulates c-Myc, Cyclin D2 and Bcl-xL in U266 cells. Both c-Myc and Cyclin D2 were decreased in a dose-dependent manner by AZD1480 at 24 h, whereas Bcl-xL was decreased after 48 h by AZD1480 treatment. At 48 h post-treatment the inhibition of c-Myc and Cyclin-D2 was even more dramatic ( Figure 4b ). We did not observe IL-6-dependent upregulation of Mcl-1, which was downregulated by AZD1480. IL-6 We then analyzed the protein levels of c-Myc, Mcl-1, Cyclin D2 and Bcl-xL in U266 and Kms.11 cells pretreated with AZD1480 and then stimulated with IL-6, demonstrating that AZD1480 inhibits the IL-6-dependent expression of c-Myc and Cyclin D2 in U266 and Kms.11 cells, respectively (Figure 4c ). These results suggest that AZD1480 could inhibit myeloma cell proliferation and survival through the downregulation of c-Myc or Cyclin D2.
AZD1480 effects on myeloma cells cocultured in vitro with BM stroma cells
The BM stromal environment is a major factor in myeloma cell growth and resistance to chemotherapy. 29, 30 We first investigated whether AZD1480 has cytotoxic effects in the human BM stroma-derived HS-5 cell line. Figure 5a shows that the proliferation of HS-5 cells was not affected at concentrations in the IC 50 range for Kms.11 cells. We then tested the effect of the BM environment on myeloma cell response to AZD1480. To determine if STAT3 and MAPK signaling pathways are downregulated by AZD1480 in myeloma cells cocultured with BM stromal cells, we treated U266 and Kms.11 cell lines for 2 h after being cocultured for 2 days with HS-5 cells monolayer (Figure 5c ). In this setting, we observed a significant decrease in the level of stroma-induced STAT3 phosphorylation in U266 cells, although stroma-induced phosphorylation of MAPK was minimal. In contrast, we did not observe any significant increase in stroma-induced phospho-JAK2/STAT3 levels in the Kms.11 cell line and AZD1480 had no apparent effect on JAK2/STAT3 phosphorylation in these cells, instead there was a decrease in phospho-MAPK levels, suggesting that stromal cells are modulating AZD1480 responses differently compared with cells cultured with IL-6.
AZD1480 inhibits both JAK2 and FGFR3 activity in vitro
Recurrent translocations have been identified in approximately 50% of primary MM patient samples; the most frequent of these translocations involves the receptor tyrosine kinase FGFR3. 31, 32 As Kms.11 cells possess translocated FGFR3, and AZD1480 has activity against FGFR1, 18 combined with the finding that Kms.11 cocultured with BM stromal cells are sensitive to AZD1480 without showing inhibition of phospho-STAT3, we hypothesized that AZD1480 may inhibit FGFR3 signaling in these settings. Figure 5d demonstrates that AZD1480 inhibits phosphorylation of FGFR3 in Kms.11 cells cocultured with HS-5 BM stromal cells. These results suggest that inhibition of FGFR3 signaling is very likely driving sensitivity of Kms.11 cells, rather than JAK/STAT signaling, in these settings.
To confirm the finding that AZD1480 inhibits FGFR3 signaling, we examined the effect of AZD1480 on b-FGFdependent FGFR3 phosphorylation in Kms.11 cells pretreated with AZD1480 and then stimulated with b-FGF. Figure 6a shows that b-FGF-induced phosphorylation of FGFR3 was inhibited in Kms.11 cells at 0.25 mM and virtually abolished at 1 mM, which are similar doses that inhibit IL-6-induced phosphorylation of STAT3 in U266 and Kms.11 cells. We postulated that Kms.11 cells may be sensitive to downregulation of FGFR3 by siRNA. Figure 6b In vitro kinase assays (Figure 7 ) confirmed that AZ1480 inhibits both JAK2 and FGFR3 activity, consistent with role of JAK2/ STAT3 and FGFR3 in the biological effects mediated by AZD1480. Nevertheless, we do not exclude the possibility that other pathways may be involved in the response to AZD1480. Figure 7 also shows that AZD1480 is effective against JAK2 and FGFR3 activity at lower doses than another JAK2 or FGFR3 inhibitor. Compared with a commercially available JAK2 inhibitor, AZD1480 is even more potent in terms of cytotoxicity (Supplementary Figure 3) .
AZD1480 blocks growth of Kms.11. xenografts associated with inhibition of JAK2/STAT3 and FGFR3
The presence of translocated FGFR3 in patients is associated with shorter duration of remission, higher relapse rate and shorter survival. 33 Thus, the Kms.11 cell line represents more aggressive disease, and for this reason we considered Kms.11 as a good model to study the effect of AZD1480 in vivo. In NOD/ SCID IL2Rg-null mice treated twice a day with 30 mg/kg AZD1480, we observed statistically significant tumor growth inhibition (Figure 8a ). After only 6 days from the first treatment, we observed regression of the tumor in 80% of the mice for as much as 40% volume reduction compared with the initial tumor volume before the first treatment. The average tumor size of the treated group was approximately six and 12 times smaller than the average of tumor size of control vehicle group, 6 and 12 days post treatment, respectively. Similar data were observed in a separate experiment with athymic nude mice (data not shown). Regression of the tumor was associated with complete inhibition of STAT3, FGFR3 phosphorylation and modest inhibition of Cyclin D2 (approximately 50% reduction, P ¼ 0.0286) in tumors harvested 2 h after dosing (Figures 8b,c) . However, we did not observe consistent inhibition of phospho-MAPK among tumors treated with AZD1480 (data not shown).
AZD1480 causes loss of viability of primary MM cells cultured in vitro and enhances the sensitivity to chemotherapy
We next determined whether AZD1480 treatment could also be active against primary plasma cells isolated from BM samples of MM patients. Table 2 indicates that all four patient samples analyzed responded to the AZD1480 treatment with an increase in the percentage of nonviable cells in a dose-dependent manner. Importantly, one of these samples was treated with AZD1480 in the presence of BM stromal cells and responded even better than when it was treated in the absence of stroma. In contrast, no cytotoxic effects were observed in five normal CD138 þ samples at the same doses ( Figure 9 ). The BM stromal environment is a major factor in myeloma cell resistance to chemotherapeutic agents such as dexamethasone, 34 melphalan and mitoxantrone. 30, 35 We tested the effect of the BM environment on myeloma cell response to AZD1480 in combination with doxorubicin and melphalan in terms of induction of cell death (data not shown). Coculturing of Kms.11 cells with human BM stromal HS-5 cells does not protect the myeloma cells to doxorubicin compared with the controls that were not cocultured. Protection from melphalan treatment was also not observed. AZD1480 potentiated the cell death induced by doxorubicin and melphalan in Kms.11 grown alone and even more if cocultured with HS-5 cells. This enhanced response with combination treatment represents an additive to synergistic response (Table 3) .
Discussion
In this study, we investigated the biologic mechanism of action of the novel small-molecule JAK kinase inhibitor AZD1480 on human myeloma cells. We found that AZD1480, at low micromolar concentrations, inhibits the viability of cell lines that express constitutively activated STAT3 (U266, IM-9), or translocated FGFR3 (Kms.18) or both (Kms.11, OPM-2). In contrast, higher concentrations of AZD1480 are required to inhibit cells (8226, NCI-H929 and MM1.S) that lack both FGFR3 overexpression and activated STAT3 and are not growth stimulated by IL-6. 13, 24 Moreover, the lack of inhibition of proliferation and viability of BM stromal cells and PB mononuclear cell derived from healthy donors indicates that the drug may not have cytotoxic effects in normal cells. Anti-tumor activity of AZD1480 was observed also in myeloma cells growth stimulated by IL-6. We found that AZD1480 abrogates IL-6-induced activation of JAK2, tyrosine phosphorylation of STAT3 and phosphorylation of MAPK. AZD1480 suppresses the proliferative response to IL-6 with concomitant decreases in the protein levels of Cyclin D2 in these cells. Cyclin D2 is known to be important in the growth of MM cells and has been shown to be regulated by STAT3 in MM. 36, 37 That IL-6 activates MAPK through a Ras-dependent cascade is well established. 12, 38 Our finding that AZD1480 inhibits IL-6-induced phosphorylation of MAPK suggests that the drug may also act through inhibition of JAK1 activity, which in turn is not able to activate JAK2. This is consistent with potency of AZD1480 for JAK1 in enzymatic assays, 18 and previous data indicating that JAK1 has a major role in IL-6-mediated activation of STAT3. 39 Whether AZD1480 is acting mainly through JAK1 or JAK2 requires further investigation.
Translocations involving FGFR3 do not directly target a cyclin D gene, but they are associated with a high level of Cyclin D2 expression. 36 Cyclin D2 leads to growth promotion and survival in MM. 40 We show that AZD1480 downregulates Cyclin D2 in both U266 and Kms.11 cells cultured in the presence or absence of IL-6, suggesting that Cyclin D2 is a major downstream target of AZD1480-induced inhibition of STAT3 activity in an IL-6-dependent and -independent manner. AZD1480 may downregulate Cyclin D2 by inhibiting FGFR3 and/or inhibiting STAT3 binding to the c-maf promoter, 37 as Cyclin D2 is a target of c-maf. 40 8226 cells, which among the cell lines analyzed here are the least sensitive to AZD1480 in terms of viability inhibition, do not exhibit downregulation of Cyclin D2, suggesting that in those cells Cyclin D2 may be regulated by different pathways. This finding supports the conclusion that Cyclin D2 could be a major mediator in the response to AZD1480. We also confirmed that c-Myc, a common secondary translocation partner in MM, 41 is upregulated upon IL-6 stimulation of MM cells 42 and we found that AZD1480 downregulates c-Myc expression in an IL-6-dependent manner.
Mcl-1 and Bcl-xL are implicated in the survival of myeloma cells, 43, 44 and expression of these proteins can be selectively downregulated by dominant/negative STAT3 or JAK2 inhibitors.
11, 45 We did not observe IL-6-inducible upregulation of Mcl-1, in contrast to what has been shown in different MM cell lines 28, 46 and in CD45 þ U266 cells, 47 but consistent with other cells that exhibited high levels of Mcl-1 expression and were unaffected by IL-6.
48,49 Nevertheless, we observed that Mcl-1 is downregulated by AZD1480. We also observed that IL-6 induces upregulation of Bcl-xL in U266 and AZD1480 downregulates Bcl-xL at higher concentrations associated with complete inhibition of STAT3 phosphorylation.
BM stroma cells induce activation of pathways involved in proliferation, survival, migration and drug resistance in MM cells. 29, 50 Moreover, MM cells may become independent of the STAT3 pathway in the presence of BM stroma. 30, 51 We found that myeloma cells are equally sensitive to AZD1480 regardless of whether they were cultured alone or in the presence of BM stromal cells. However, STAT3 and MAPK pathways are differentially deregulated in the presence of stromal cells compared with what occurs in cells cultured in the presence of IL-6. In the presence of IL-6, both U266 and Kms.11 cell lines treated with AZD1480 exhibit downregulation of IL-6-induced phosphorylation of STAT3 and MAPK. When cocultured with stromal cells, the two cell lines exhibit differential inhibition of STAT3 or MAPK activity in U266 or Kms.11 cells, respectively, demonstrating that under these conditions combined disruption of both MAPK and STAT3 pathways is not required to induce MM cell apoptosis. Therefore, in this setting, FGFR3 signaling inhibition may be the key driver of response to AZD1480 for Kms.11 cells rather than STAT3 inhibition; these data are , respectively, four tumor samples from each group were harvested 2 h post dosing; the weight average was 1.52 and 0.24 g in the vehicle and drug-group mice, respectively. Whole-cell lysates were prepared and subjected to western blot analysis or immunoprecipitation, followed by immunoblot (c). Equal amounts of protein were analyzed. supported by the finding that AZD1480 inhibits b-FGF-mediated phosphorylation of FGFR3. It is possible that the release of b-FGF from BM stromal cells is predominant over IL-6 release, and, hence, Kms.11 cells may become more dependent on b-FGF/FGFR3 signaling than IL-6/JAK2/STAT3 in the presence of stromal cells. Importantly, we observed strong inhibition of both STAT3 and FGFR3 activity in Kms.11-bearing mice treated with AZD1480, suggesting that the in vivo microenvironment influences signaling in the tumor in a different manner than in vitro conditions in which tumor cells are cocultured with BM stromal cells. Inhibition of constitutive STAT3 activity sensitizes MM cells to apoptosis induced by conventional chemotherapy. 52 Notably, our results indicate that AZD1480 sensitizes myeloma cells to doxorubicin and melphalan, regardless of whether they were cultured alone or in the presence of BM stromal cells. These findings raise the possibility that combination with AZD1480 may further enhance clinical response to conventional chemotherapy in MM patients.
Our transfection experiments indicate that both STAT3 and FGFR3 constructs protect Kms.11 cells from AZD1480-induced loss of viability, suggesting that inhibition of STAT3, as well as inhibition of FGFR3, contribute to efficacy of AZD1480 in those cells. These results indicate that both STAT3 and FGFR3 may be necessary for response of Kms.11 cells to AZD1480, and the inhibition of only one of these pathways may be not sufficient for induction of viability loss in response to AZD1480 treatment. It is possible that both STAT3 and FGFR3 regulate the expression of Cyclin D2, and this may explain why Kms.11 cells are more sensitive than U266 cells in terms of apoptosis and inhibition of proliferation. Our kinase assays demonstrate that AZD1480 is active against both JAK2 and FGFR3, possibly explaining why cells that possess constitutively activated STAT3 or translocated FGFR3 are more sensitive than those that lack both; cells expressing both activated STAT3 and translocated FGFR3 are the most sensitive. AZD1480 activity on JAK2 and FGFR3 is even greater than other JAK2 and FGFR3 inhibitors analyzed in our kinase assays. These observations do not exclude the possibility that AZD1480 inhibits other kinases, but support the potential of AZD1480 as a dual JAK/FGFR inhibitor for targeting myeloma cells.
In sum, AZD1480 suppresses the JAK2/STAT3 and FGFR3 signaling pathways, downregulates Cyclin D2 protein expression, and inhibits growth and survival of human myeloma cells in vitro, in vivo and in coculture with BM stroma. Combined with its potential to enhance sensitivity to chemotherapy, our findings provide a compelling rationale for clinical trials of AZD1480 in patients with MM.
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